Bridge Medicines

Deerfield founded Bridge Medicines in October 2016 and committed to fund its operations. Bridge is a partnership between Deerfield, Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceuticals and another venture firm to establish a new drug discovery company. Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

Press releases

Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept
October 2016

Bridge Medicines Accepts Novel Small Molecule Targeting Basal Cell Carcinoma As First Drug Candidate for Development
March 2018

Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer
April 2018

Bridge Medicines Enters Agreement with Memorial Sloan Kettering to Develop Kidney‐Specific Delivery Platform for the Treatment of Acute Kidney Injury
July 2018